| Literature DB >> 30545852 |
Joon-Yong An1, Kevin Lin2, Lingxue Zhu2, Donna M Werling1, Shan Dong1, Harrison Brand3,4,5, Harold Z Wang3, Xuefang Zhao3,4,5, Grace B Schwartz1, Ryan L Collins3,4,6, Benjamin B Currall3,4,5, Claudia Dastmalchi1, Jeanselle Dea1, Clif Duhn1, Michael C Gilson1, Lambertus Klei7, Lindsay Liang1, Eirene Markenscoff-Papadimitriou1, Sirisha Pochareddy8, Nadav Ahituv9,10, Joseph D Buxbaum11,12,13,14, Hilary Coon15,16, Mark J Daly5,17,18, Young Shin Kim1, Gabor T Marth19,20, Benjamin M Neale5,17,18, Aaron R Quinlan16,19,20, John L Rubenstein1, Nenad Sestan8, Matthew W State1,10, A Jeremy Willsey1,21,22, Michael E Talkowski23,4,5,24, Bernie Devlin25, Kathryn Roeder26,27, Stephan J Sanders28,10.
Abstract
Whole-genome sequencing (WGS) has facilitated the first genome-wide evaluations of the contribution of de novo noncoding mutations to complex disorders. Using WGS, we identified 255,106 de novo mutations among sample genomes from members of 1902 quartet families in which one child, but not a sibling or their parents, was affected by autism spectrum disorder (ASD). In contrast to coding mutations, no noncoding functional annotation category, analyzed in isolation, was significantly associated with ASD. Casting noncoding variation in the context of a de novo risk score across multiple annotation categories, however, did demonstrate association with mutations localized to promoter regions. We found that the strongest driver of this promoter signal emanates from evolutionarily conserved transcription factor binding sites distal to the transcription start site. These data suggest that de novo mutations in promoter regions, characterized by evolutionary and functional signatures, contribute to ASD.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30545852 PMCID: PMC6432922 DOI: 10.1126/science.aat6576
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728